首页> 外文OA文献 >FRI0092 SAFETY AND EFFICACY OF FILGOTINIB IN ACTIVE RHEUMATOID ARTHRITIS BY PRIOR BIOLOGICAL DMARD EXPOSURE IN PATIENTS WITH PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR)

【2h】

FRI0092 SAFETY AND EFFICACY OF FILGOTINIB IN ACTIVE RHEUMATOID ARTHRITIS BY PRIOR BIOLOGICAL DMARD EXPOSURE IN PATIENTS WITH PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR)

机译：Fri0092 Frivootinib在活性类风湿性关节炎中的安全性和有效性通过先前的生物DMARD在患者对生物DMARD（BDMARD-IR）的不容忍（BDMARD-IR）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Mark C. Genovese; Kenneth Kalunian; Jacques-Eric Gottenberg; Neelufar Mozaffarian; Beatrix Bartok; Franziska Matzkies; Jie Gao; Ying Guo; Kurt de Vlam; David Walker; Tsutomu Takeuchi;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis [J] . Jeroen P Jansen, Felicity Buckley, Fred Dejonckheere, Health and Quality of Life Outcomes . 2014,第1期

机译：生物学作为单药治疗的比较疗效和与甲氨蝶呤对患者的甲氨蝶呤报告的类风湿性关节炎患者的结果（优点）对常规DMARD的反应不足 - 一种系统审查和网络元分析
2. Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use [J] . Takahashi Nobunori, Fujibayashi Takayoshi, Kida Daihei, Rheumatology international. . 2015,第10期

机译：甲氨蝶呤和他克莫司的同时使用可增加具有DMARD生物使用史的类风湿关节炎患者对abatacept的临床反应
3. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial [J] . Peter C. Taylor, Didier Saurigny, Jiri Vencovsky, Arthritis research & therapy. . 2019,第1期

机译：抗风湿性关节炎（RA）患者对甲氨蝶呤背景疗法的反应不足，对抗氨甲蝶呤疗法的反应不足或不耐受的类风湿性关节炎（RA）患者抗粒细胞巨噬细胞集落刺激因子（GM-CSF）配体的人类单克隆抗体那米单抗的疗效和安全性-TNF（肿瘤坏死因子）生物疗法：一项随机对照试验
4. Active learning for Bayesian network models of biological networks using structure priors [C] . Larjo Antti, Lahdesmaki Harri 2013 IEEE International Workshop on Genomic Signal Processing and Statistics . 2013

机译：利用结构先验主动学习生物网络的贝叶斯网络模型
5. “Don’t Rock the Boat”: A Qualitative Narrative Study Exploring Rheumatoid Arthritis Patients’ Experience of Illness and Biologics [D] . Rachich, Meagan . 2020

机译：“不要摇滚船”：探索类风湿性关节炎患者的疾病和生物学经验的定性叙事研究
6. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis [O] . Jeroen P Jansen, Felicity Buckley, Fred Dejonckheere, 2014

机译：生物制剂作为单一疗法并与甲氨蝶呤联用对类风湿性关节炎患者对常规DMARDs反应不足的患者报告的结局（PRO）的比较功效–系统评价和网络荟萃分析
7. FRI0154 SAFETY AND EFFICACY OF FILGOTINIB IN PATIENTS AGED 65 YEARS AND OLDER: RESULTS FROM A PHASE 3 STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR) [O] . Kenneth Kalunian, Jacques-Eric Gottenberg, Mark C. Genovese, 2019

机译：Fri0154菲尔替尼对65岁及以上患者的安全性和有效性：活性类风湿性关节炎患者的第3阶段研究结果和对生物DMARDS的响应或不容忍（BDMARD-IR）的患者

FRI0092 SAFETY AND EFFICACY OF FILGOTINIB IN ACTIVE RHEUMATOID ARTHRITIS BY PRIOR BIOLOGICAL DMARD EXPOSURE IN PATIENTS WITH PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR)

著录项

相似文献

相关主题

期刊订阅